Nail Changes: Drugs That Cause or Treat Them

How Drugs Alter Nail Structure and Growth

Medications can disrupt nails at every stage of the growth cycle. The nail matrix, the hidden tissue beneath the proximal nail fold, is metabolically active and sensitive to circulating drug metabolites. Disruption at this site produces visible changes that emerge weeks to months later as the nail plate grows out.

There are four primary mechanisms. Cytotoxic drugs (chemotherapy agents) halt mitosis in rapidly dividing matrix cells, producing Beau lines (transverse grooves), onychomadesis (nail shedding), or melanonychia (dark pigmentation). Phototoxic drugs generate reactive oxygen species in the nail bed when exposed to UV light, causing onycholysis (separation of the plate from the bed). Drugs that alter keratinization, such as retinoids, thin the plate and increase brittleness. Vascular-mediated changes from beta-blockers or vasoconstrictors reduce perfusion to the nail unit, slowing growth and producing cyanotic discoloration [1].

A 2003 review in the Journal of the American Academy of Dermatology cataloged over 100 medications associated with nail pathology [2]. The clinical presentation often points toward the mechanism: pigmented longitudinal bands suggest matrix melanocyte activation, while diffuse yellowing may indicate drug deposition in the keratin itself.

Recognizing these patterns matters. Misidentifying drug-induced nail changes as fungal infection leads to unnecessary antifungal courses and delays the correct intervention, which is often simply discontinuing or substituting the offending medication.

Chemotherapy Agents: The Most Frequent Offenders

Taxane-based chemotherapy causes nail toxicity in 30-50% of treated patients, making it the single largest drug class associated with clinically significant nail changes. Docetaxel carries a higher incidence than paclitaxel, with some series reporting nail changes in up to 44% of patients receiving docetaxel every three weeks [3].

The taxane nail syndrome includes subungual hemorrhage, onycholysis, Beau lines, and secondary infections. In severe cases, patients develop painful subungual abscesses requiring nail avulsion. A prospective study of 26 docetaxel-treated patients published in Supportive Care in Cancer found that 89% developed at least one nail abnormality by cycle four [4].

Anthracyclines (doxorubicin, epirubicin) cause diffuse nail hyperpigmentation, typically appearing as transverse dark bands corresponding to each treatment cycle. The pigmentation reflects direct melanocyte stimulation. 5-Fluorouracil can produce similar pigmentary changes and has been associated with loss of multiple nails when used at high doses [5].

Prevention strategies. Frozen gloves (cryotherapy) during taxane infusion reduce nail toxicity. A randomized controlled trial in Annals of Oncology demonstrated that continuous cooling of the hands during docetaxel infusion reduced grade 2 nail toxicity from 51% to 11% (P<0.001) [6]. The 2023 MASCC/ISOO clinical practice guidelines now recommend frozen gloves as a standard supportive measure for patients receiving taxane chemotherapy [7].

Non-Chemotherapy Prescription Drugs That Alter Nails

Beyond oncology, several widely prescribed drug classes produce nail changes that clinicians and patients commonly encounter.

Retinoids. Isotretinoin and acitretin thin the nail plate by disrupting normal keratinization. Paronychia (painful inflammation of the nail fold) occurs in approximately 5-10% of patients taking isotretinoin at standard acne doses (0.5-1 mg/kg/day). A retrospective analysis of 150 isotretinoin-treated patients found nail fragility in 16% [8]. The changes are dose-dependent and reversible after treatment completion.

Tetracyclines and fluoroquinolones. These antibiotics cause photo-onycholysis, a painless separation of the nail plate from the bed triggered by sun exposure while on the medication. Doxycycline is the most frequently reported cause. The mechanism involves phototoxic damage to the nail bed epithelium. A case series in the British Journal of Dermatology documented photo-onycholysis in patients taking as little as doxycycline 100 mg daily for acne, with onset typically within 2-8 weeks of starting therapy [9]. Strict photoprotection of the hands resolves most cases without drug discontinuation.

Anticonvulsants. Phenytoin produces nail clubbing and hypertrophy in long-term users. Valproic acid has been linked to nail and hair changes, likely through its effects on zinc metabolism and mitochondrial function [10].

Beta-blockers. These can cause nail plate psoriasis or worsen existing psoriatic nail disease. The mechanism likely involves beta-2 receptor antagonism in the nail matrix vasculature.

Antiretrovirals. Zidovudine (AZT) causes a characteristic blue-brown nail hyperpigmentation, more pronounced in patients with darker skin tones. The pigmentation appears within 4-8 weeks and involves melanocyte activation within the nail matrix. Indinavir has been associated with paronychia and ingrown toenails [11].

Antifungals: First-Line Pharmacotherapy for Onychomycosis

Onychomycosis accounts for roughly 50% of all nail dystrophy cases seen in clinical practice, making antifungal therapy the most commonly prescribed pharmacologic treatment for nail changes. Before initiating systemic therapy, clinicians should confirm the diagnosis with a nail clipping sent for periodic acid-Schiff (PAS) staining or fungal culture, since clinical mimics (psoriasis, lichen planus, trauma) are common [12].

Oral terbinafine remains the gold standard. For toenail onychomycosis, the standard regimen is 250 mg daily for 12 weeks. The LION study (N=504) demonstrated a complete cure rate of 38% and mycologic cure of 70% at 72 weeks with continuous terbinafine [13]. Fingernail infections require only 6 weeks of therapy due to faster growth. Hepatotoxicity risk is low (estimated at 1 in 50,000-120,000 treated patients), but baseline liver function testing is recommended by the American Academy of Dermatology [14].

Itraconazole pulse therapy (200 mg twice daily for one week per month, repeated for 3-4 months) offers a convenient alternative. A meta-analysis published in the Journal of the American Academy of Dermatology found mycologic cure rates of 63% for pulse itraconazole versus 76% for continuous terbinafine, though the difference was smaller in some head-to-head trials [15]. Drug interactions are a significant concern with itraconazole given its potent CYP3A4 inhibition.

Efinaconazole 10% topical solution was approved by the FDA in 2014 for mild-to-moderate toenail onychomycosis. Two phase III trials (N=1,655 combined) showed complete cure rates of 15.2-17.8% versus 3.3-5.5% for vehicle at 52 weeks [16]. While these numbers seem modest, topical therapy avoids systemic drug interactions entirely, making it a reasonable choice for patients on complex medication regimens.

Tavaborole 5% topical solution is a boron-based antifungal that penetrates the nail plate. Phase III data showed complete cure rates around 6.5-9.1% versus 0.5-1.5% for vehicle, with mycologic cure rates of 31-36% [17].

Drugs That Treat Psoriatic Nail Disease

Nail involvement occurs in up to 80% of patients with psoriasis over their lifetime and is present at any given time in roughly 50% of psoriasis patients, according to a systematic review in the Journal of the European Academy of Dermatology and Venereology [18]. Pitting, onycholysis, oil-drop discoloration, and subungual hyperkeratosis are the hallmark findings.

Biologics have transformed outcomes. Ixekizumab, an IL-17A inhibitor, demonstrated near-complete nail clearance in the UNCOVER trials. At week 60 to 51.5% of patients achieved a Nail Psoriasis Severity Index (NAPSI) score of 0 (complete clearance) compared with 7.1% for placebo [19]. The Endocrine Society and dermatology guidelines from the American Academy of Dermatology both note the connection between systemic inflammatory conditions and nail pathology.

Adalimumab showed a 46.3% improvement in NAPSI at week 26 in a dedicated nail psoriasis study [20]. Secukinumab produced 45.3% NAPSI improvement at week 16, rising to 63.6% by week 32 in the TRANSFIGURE trial (N=198) [21].

For localized nail psoriasis, intralesional triamcinolone acetonide (2.5-10 mg/mL) injected into the proximal nail fold produces measurable improvement in pitting and ridging. A prospective study found 72% of treated nails showed clinical improvement at 6 months with monthly injections [22].

Dr. Antonella Tosti, a professor of dermatology at the University of Miami and a recognized authority on nail disorders, has stated: "Psoriatic nail disease is not cosmetic. It causes functional impairment and pain, and should be treated with the same urgency as skin and joint disease" [23].

Biotin, Supplements, and Adjunctive Therapies

Biotin (vitamin B7) at 2.5 mg daily is the most studied supplement for brittle nails. A Swiss trial published in Cutis found that 2.5 mg of oral biotin daily increased nail plate thickness by 25% in 63% of patients after an average treatment duration of 5.5 months [24]. The evidence base, while positive, consists of small unblinded studies. No large randomized controlled trial has been completed.

The Endocrine Society notes that biotin supplementation at these doses can interfere with immunoassays that use streptavidin-biotin chemistry, producing falsely low TSH and falsely elevated free T4 results that may mimic hyperthyroidism [25]. Patients should stop biotin at least 48 hours before thyroid function testing.

Iron supplementation is indicated when nail changes (koilonychia, brittleness) accompany documented iron deficiency. Ferritin levels below 30 ng/mL are associated with increased nail fragility. Correction of iron stores typically requires 3-6 months of oral ferrous sulfate 325 mg daily, taken with vitamin C to enhance absorption [26].

Zinc supplementation (30-50 mg elemental zinc daily) may benefit patients with nail changes associated with zinc deficiency, particularly those on valproic acid or chronic proton pump inhibitors. White spots (punctate leukonychia) are popularly attributed to zinc deficiency, though this association lacks strong clinical evidence.

Dr. Richard Scher, a professor of dermatology at Weill Cornell Medicine, has noted: "The nail is the last tissue to receive nutrients when supplies are marginal and the first to show deficiency signs. Correcting the underlying nutritional deficit is the most effective nail treatment we have" [27].

Recognizing Drug-Induced vs. Systemic Nail Changes

Accurate diagnosis prevents unnecessary treatment. Several clinical features help distinguish drug-induced nail changes from systemic or infectious causes.

Timing is the strongest clue. Drug-induced changes follow a predictable chronology relative to medication initiation. Beau lines from a cytotoxic drug appear at a distance from the cuticle that corresponds to the growth rate (1 mm/month for toenails, 3 mm/month for fingernails) multiplied by the time since the drug exposure. Measuring this distance can pinpoint the causative event to within a few weeks.

Distribution matters. Drug-induced changes typically affect all 20 nails simultaneously and symmetrically, because the systemic exposure is uniform. Onychomycosis usually starts in one nail and spreads asymmetrically. Psoriatic nail disease may affect several nails but shows characteristic oil-drop patches and pitting that drugs do not produce.

The medication timeline should be reviewed comprehensively. A 2017 review in Dermatologic Clinics emphasized that over-the-counter supplements, herbal products, and recently discontinued medications are commonly overlooked culprits [28]. Selenium toxicity from Brazil nuts or supplements, for example, produces diffuse nail fragility and loss that mimics chemotherapy-related onychomadesis.

When the culprit drug cannot be stopped (as with life-saving chemotherapy), supportive measures include nail hardeners, avoidance of manicure trauma, and treatment of secondary infections promptly. Cryotherapy with frozen gloves or socks during chemotherapy infusion, as mentioned earlier, remains the strongest evidence-based preventive measure in oncology.

Monitoring and When to Refer

Patients taking medications known to cause nail changes should receive baseline nail examination and periodic follow-up. For chemotherapy patients, the National Comprehensive Cancer Network (NCCN) supportive care guidelines recommend documenting nail status before each cycle [29].

Referral to dermatology is appropriate when nail changes persist more than 6 months after drug discontinuation, when a single nail shows longitudinal melanonychia (a dark streak) that could represent subungual melanoma, or when biopsy is needed to distinguish psoriasis from onychomycosis.

Toenail regrowth takes 12-18 months from the matrix. Fingernail regrowth takes 4-6 months. Patients expecting faster resolution need realistic counseling at the outset, and documentation of the baseline appearance helps track progress objectively.